Evidence map›Paper›PMID 40091506›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation.

Yu Wang, Hui Xue, Xiaohui Zhu, Dong Lin, Zheng Chen, Xin Dong, Junru Chen, Mingchen Shi, Yuchao Ni, Jonathan Cao and 11 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Yu WangDepartment of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, V5Z 1M9, Canada.ORCID https://orcid.org/0000-0001-8731-0156
Hui XueDepartment of Experimental Therapeutics, BC Cancer, Vancouver, V5Z 1L3, Canada.
Xiaohui ZhuThe First Affiliated Hospital of Jinan University, First Clinical Medical College, Jinan University, Guangzhou, 510632, P. R. China.
Dong LinVancouver Prostate Centre, Vancouver, V6H 3Z6, Canada.
Zheng ChenThe First Affiliated Hospital of Jinan University, First Clinical Medical College, Jinan University, Guangzhou, 510632, P. R. China.
Xin DongDepartment of Experimental Therapeutics, BC Cancer, Vancouver, V5Z 1L3, Canada.
Junru ChenDepartment of Urology, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China.
Mingchen ShiDepartment of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, V5Z 1M9, Canada.
Yuchao NiDepartment of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, V5Z 1M9, Canada.
Jonathan CaoDepartment of Cell and Systems Biology, University of Toronto, Toronto, M5S 3G5, Canada.
Rebecca WuDepartment of Experimental Therapeutics, BC Cancer, Vancouver, V5Z 1L3, Canada.
Connie KangDepartment of Experimental Therapeutics, BC Cancer, Vancouver, V5Z 1L3, Canada.
Xinyao PangDepartment of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, V5Z 1M9, Canada.
Francesco CreaCancer Research Group, School of Life Health and Chemical Sciences, The Open University, Milton Keynes, MK7 6AA, UK.
Yen-Yi LinDepartment of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, V5Z 1M9, Canada.
Colin C CollinsDepartment of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, V5Z 1M9, Canada.
Martin E GleaveDepartment of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, V5Z 1M9, Canada.
Abhijit ParoliaMichigan Center for Translational Pathology, Department of Urology, University of Michigan Medical School, Rogel Cancer Center, University of Michigan Hospital, Ann Arbor, 48109, USA.
Arul ChinnaiyanMichigan Center for Translational Pathology, Department of Urology, University of Michigan Medical School, Rogel Cancer Center, University of Michigan Hospital, Ann Arbor, 48109, USA.
Christopher J OngDepartment of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, V5Z 1M9, Canada.
Yuzhuo WangDepartment of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, V5Z 1M9, Canada.ORCID https://orcid.org/0000-0002-9749-8591

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
BC Cancer Foundation 1PRRG012Cancer Research Society PIN-840847CIHR 153073CIHR 153081CIHR 173338CIHR 175238CIHR 180554CIHR 186331Lotte & John Hecht Memorial Foundation and Canadian Cancer Society Research Institute (CCSRI) 707683NCI NIH HHS P50 CA097186NIH HHS P50CA097186Prostate Cancer FoundationProstate Cancer UK RIA22-ST2-006Terry Fox Research Institute 1109U.S. Department of Defense W81XWH-21-1-0300
6 · The paper itself

Abstract

Prostate cancer (PCa) stands as a leading cause of cancer-related mortality among men, with treatment-induced neuroendocrine prostate cancer (NEPC) posing a challenge as an ARPI-resistant subtype. The role of transcription factors (TFs) in PCa progression and NEPC transdifferentiation remains inadequately understood, underscoring a critical gap in current research. In this study, an internal Z score-based approach is developed to identify lineage-specific TF profiles in prostatic adenocarcinoma and NEPC for a nuanced understanding of TF expression dynamics. Distinct TF profiles for adenocarcinoma and NEPC are unveiled, identifying 126 shared TFs, 46 adenocarcinoma-TFs, and 56 NEPC-TFs, validated across multiple cohorts. Gene Ontology is employed to validate their biological and functional roles in PCa progression. Implications are revealed in cell development, differentiation, and lineage determination. Knockdown experiments suggest that lineage-TFs are functionally important in maintaining lineage-specific cell proliferation. Additionally, a longitudinal study on NE transdifferentiation highlights dynamic TF expression shifts, proposing a three-phases hypothesis for PCa progression mechanisms. This study introduces a groundbreaking approach for deciphering the TF landscape in PCa, providing a molecular basis for adenocarcinoma to NEPC progression, and paving the way for innovative treatment strategies with potential impact on patient outcomes.

Indexed as

Cell TransdifferentiationProstatic NeoplasmsTranscription FactorsAdenocarcinomaDisease ProgressionGene Expression Regulation, NeoplasticHumansMaleTranscription FactorsadenocarcinomaDe‐differentiationdormancylineage plasticityNE transdifferentiationneuroendocrine prostate cancertranscription factor

Identifiers

PMID40091506
PMCPMC12120771

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.